,0,1,2,3,4,5
0,,Accession ID: NGSO-221209001,,,,Page 5 of 76
1,,"Patient Name: LAN ZHENG,MEI-CHAN",,,,
2,,,Diagnosis: gastric cancer,,"Report Date: Dec 19,2022",
3,YOUR LAB,"Report Date: Dec 19,2022",,,,
4,,,,Approved Therapies,,
5,,,,,Associated With,Clinical
6,Gene /Variant,Allelic Fraction,Gastric Cancer,Other Indications,Resistance,Trials
7,,,,pertuzumab,,
8,,,,trastuzumab,,
9,,,,emtansine,,
10,,,,tucatinib,,
11,ERBB3,48.0% (of 629,,afatinib,,
12,c.3380G>A,reads),p.Rl127H,bosutinib,,
13,g.56101239G>A,,,dacomitinib,,
14,Tier 3,,,neratinib,,
15,Uncertain,,,osimertinib,,
16,Significance,,,osimertinib,,
17,FGFR4,48.0% (of 145 reads),,erdafitinib,,
18,c.1871A>C,,,futibatinib,,
19,p.N624T,,,futibatinib,,
20,g.177096106A>C,,,infigratinib,,
21,Tier 3,,,lenvatinib,,
22,Uncertain,,,lenvatinib,ponatinib,
23,Significance,,,ponatinib,,
24,,,,regorafenib,,
25,JAK3,58.0% (of 262,,ruxolitinib,,
26,c.2660G>A,reads),,,,
27,p.R887H,,,,,
28,g.17832539C>T,,,,,
29,Tier 3,,,,,
30,Uncertain,,,,,
31,Significance,,,,,
32,Variants of Unknown Clinical Significance,,,,,
33,Gene / Variant, Allelic Fraction,Function,Classification,Assessment,
34,AMERI,6.43% (of 311 reads),normal,Tier 3,Uncertain Significance,
35,c.l646G>A,,,,,
36,p.R549Q,,,,,
37,g.6419164lC>T,,,,,
38,CRLF2,43.0% (of 326,loss,Tier 3,Uncertain Significance,
39,c.29C>T,reads),,,,
40,p.P1OL,,,,,
41,g.1202520G>A,,,,,
42,EPCAM,36.0% (of 163 reads),normal,Tier 3,Uncertain Significance,
43,c.93C>G,,,,,
